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1. Introduction
Skeletal muscle injuries are common in humans, particularly in athletes and it is important
to develop new methods to improve muscle regeneration. Skeletal muscle has good regener‐
ative ability, but the extent of muscle injury might prevent complete regeneration, especially
in terms of functional recovery. Severe lesions, like those originated by trauma associated
with loss of healthy muscular tissue and development of fibrous tissue scar and irreversible
muscular atrophy after long-term peripheral nervous injuries are examples of those situa‐
tions where regeneration is limited. An alternative approach for the restoration of the dam‐
aged skeletal muscular tissue, considered to be an ultimate treatment of some traumatic or
degenerative diseases, is the transplantation of stem cells that limit the fibrosis and the atro‐
phy of the involved muscle masses, and even imply the myocytes regeneration and local re‐
vascularization [1]. Stem cells and regenerative medicine is a fast emerging field with rapid
strides of progress and focus on human health. Successful clinical use of stem cells in regen‐
erative medicine depends on 3 important features:
i. stem cells can grow and divide indefinitely,
ii. stem cells can differentiate into specialized cell types, like skeletal muscle; and
iii. the stem cells can be delivered to the site of lesion associated to biomaterials, nowa‐
days available with excellent characteristics concerning biocompatibility.
© 2013 Pereira et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The purpose of this review is to describe the current research lines in the skeletal muscle re‐
generation field, with special emphasis to the work performed by our research group in test‐
ing different biomaterials and cellular therapies, emphasizing the use of mesenchymal stem
cells (MSCs) isolated from the Wharton’s jelly of the umbilical cord. We also focused our re‐
search in developing skeletal muscular lesion models which could be reproducible. It is im‐
portant to state, that a multidisciplinary team has a crucial role in the development of these
biomaterials associated to cellular systems, and in pre-clinical tests. MSCs comprise a rare
population of multipotent progenitor cells with a great therapeutic potential since they are
capable of self-renewal and multi-lineage differentiation. Due to this ability, MSCs appear to
be an attractive tool in the context of Tissue Engineering and cell-based therapy concerning
skeletal muscle regeneration. Several biomaterials associated to MSCs from the Wharton’s
jelly of the umbilical cord have been tested in standard lesions of the rat muscle and the re‐
sults of these tests will be discussed here. The umbilical cord matrix is an important and safe
source of MSCs with positive effects in nerve and skeletal muscle regeneration, with no ethi‐
cal or technical issues.
2. Skeletal muscle tissue
2.1. Basic structure and terminology
The muscle fibers are the basic contractile units of skeletal muscles. They are individually
surrounded by a connective tissue layer and grouped into bundles to form a skeletal muscle
[1]. Each muscle is surrounded by a layer of dense connective tissue - the epimysium -
which is continuous with the tendon. The muscle is composed of numerous bundles of mus‐
cle fibers – fascicles - which are separated from each other by another connective tissue layer
named perimysium. The endomysium is the connective tissue that separates individual
muscle fibers from each other. Mature muscle cells are termed muscle fibers or myofibers.
Each myofiber is a multinucleate syncytium formed by fusion of immature muscle cells
termed myoblasts. In the cytoplasm of each myofiber – the sarcoplasm - lays the contractile
apparatus of the cell which is composed of sarcomeres arranged in series to form myofibrils,
which give myofibers their striated appearance. The sarcomeres contain a number of pro‐
teins, including alpha-actinin — which is the major constituent of the Z band — and actin
and myosin, which are the major components of the thin and thick filaments, respectively.
The sarcoplasm, located between the myofibrils, is called the intermyofibrillar network and
contains the mitochondria, lipid, glycogen, T-tubules, and sarcoplasmic reticulum [1-3].
Skeletal muscles are highly vascularized to provide essential nutrients for muscle function.
As the myofiber matures, it is contacted by a single motoneuron and expresses characteristic
molecules for contractile function, principally different myosin heavy chain isoforms and
metabolic enzymes. Both the motoneuron and the myoblast origin have been implicated to
play a role in specifying the myofiber contractile properties, although the precise mecha‐
nisms remain to be defined [1].
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2.1.1. Fiber type
Individual adult skeletal muscles are composed of a mixture of myofibers with different
physiological properties, ranging from a slow-contracting/fatigue-resistant type to a fast-
contracting/non-fatigue-resistant type. The proportion of each fiber type within a muscle de‐
termines its overall contractile properties [1]. The slow contracting soleus muscle is rich in
myofibers expressing the slow type I myosin heavy chain isoform, whereas the fast contract‐
ing plantaris muscle is devoid of slow type I myofibers [1-3]. The most informative methods
to delineate muscle fiber types are based on specific myosin profiles, specially the myosin
heavy chain (MHC) isoform complement. According to the major MHC isoforms found in
adult mammalian skeletal muscles, the following pure fiber types exist: slow type I with
MHCIb, and three fast types, namely type IIA with MHCIIa, type IID with MHCIId and
type IIB with MHCIIb [4]. Despite having different physiological properties, the basic mech‐
anism of muscle contraction is similar in all myofiber types and is the result of a “sliding
mechanism” of the myosin-rich thick filament over the actin-rich thin filament after neuro‐
nal activation [5]. The connective tissue framework in skeletal muscle combines the contrac‐
tile myofibers into a functional unit, in which the contraction of myofibers is transformed
into movement via myotendinous junctions at their ends, where myofibers attach to the
skeleton by tendons. Thus the functional properties of skeletal muscle depend on the main‐
tenance of a complex framework of myofibers, motor neurons, blood vessels, and extracellu‐
lar connective tissue matrix [1].
2.2. Regeneration of the skeletal muscle
Regeneration is a unique adaptation of skeletal muscle that occurs in response to injury.
Following direct trauma or disease, the regeneration of skeletal muscle results in restora‐
tion, to some degree, of the original structure and function of the muscle tissue [6]. Skeletal
muscle regeneration is a physiological response of the tissue to traumatic or pathological
injuries and its progress depends on the type of damaged muscle and the extent of the injury.
Under normal conditions, the regenerated muscle is morphologically and functionally indis‐
tinguishable from undamaged muscle [1]. Regeneration resembles the process of formation of
skeletal  muscle  during embryogenesis.  Skeletal  myogenesis  begins in the somites  where
multipotencial mesodermal cells commit to the myogenic lineage. These mononucleated my‐
oblasts then fuse and form multinucleated cells (myotubes) that ultimately develop into mature
myofibers [1, 7]. During the course of muscle development, a distinct subpopulation of myo‐
blasts fails to differentiate and remains associated with the surface of the developing myofib‐
er as quiescent muscle satellite cells (SCs) in fully developed mature skeletal tissue [1, 7].
2.2.1. Satellite Cells and other cells involved in regeneration of skeletal muscle tissue
During regeneration and muscle repair, SCs fuse together or to the existing fibers to form
new muscle fibers [8]. Although the number of SCs is greatly reduced in aged muscle, those
remaining maintain an intrinsic capacity to regenerate the muscle tissue as efficiently as in
younger muscles. A vital condition for successful regeneration is the presence of SCs in the
uninjured portions of the basal membrane of the myofiber, along with its ability for reinner‐
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vation and revascularization. After a skeletal muscle injury, myofibers become completely
desintegrated via myolysis and the SCs are realeased from the basal membrane. From this
point SCs start to divide and are capable of differentiating into muscle fibers, reestablishing
myofiber’s architecture and restoring the muscle function [9, 10]. In post-natal skeletal mus‐
cle, PW1 expression is detected in SCs and a subset of interstitial cells and is markedly up-
regulated during muscle regeneration [11]. These interstitial multipotent stem cells are
extralaminal and exhibit fibroblastic morphology but do not express the same myogenic
markers such as Pax7 [10]. PW1+/Pax7– interstitial cells (PICs) are myogenic in vitro and effi‐
ciently contribute to skeletal muscle regeneration in vivo as well as generating satellite cells
and PICs. PICs show bipotential behavior in vitro, generating both smooth and skeletal mus‐
cle. Isolated PICs do not express Pax7 or MyoD, but they convert to a Pax7+/MyoD+ state be‐
fore forming skeletal muscle in vitro. PICs are not derived from a Pax3-expressing parental
cell and thus do not share a satellite cell lineage; however, PICs do express Pax3 upon con‐
version to skeletal muscle. PICs are a key cell population that cannot be recruited into the
skeletal muscle lineage in the absence of Pax7 function and is likely to contribute to the Pax7
muscle phenotype during postnatal growth. PICs are as abundant as SCs in muscle tissue
and correspond to the only population of PW1+/Pax7– cells in vivo, requiring Pax7 for their
myogenic capacity [11]. PDGFRα+ mesenchymal progenitor cells located in the muscle inter‐
stitium were also identified as being distinct from SCs. Of the muscle-derived cell popula‐
tions, only PDGFRα+ cells show efficient adipogenic differentiation both in vitro and in vivo,
being strongly inhibited by the presence of satellite cell-derived myofibres. These results
suggest that PDGFRα+ mesenchymal progenitors are the major contributor to ectopic fat cell
formation in skeletal muscle that is more conspicuous in perimysium and particularly in
perivascular space. The balance between satellite cell-dependent myogenesis and PDGFRα+
cell-dependent adipogenesis, rather than multipotency of satellite cells, has a considerable
impact on muscle homeostasis [12]. Hematopoietic and dendritic cells are also present in the
perimysium of the skeletal tissue, as well as some lymphocytes and macrophages [10].
2.2.2. Myogenic differentiation
Cells derived from Pax3-expressing cells are myofibres and SCs [11]. Once activated, SCs ex‐
press factors involved in the specification of the myogenic program, such as Pax-7, desmin,
MNFα, Myf5, MRF4 and MyoD. Activated SCs enter the cell cycle and proliferate as indicat‐
ed by the expression of factors involved in cell cycle progression, such as PCNA and by the
incorporation of BrDU. Recently, miRNAs have also been reported to regulate gene expres‐
sion in skeletal muscle. Upon activation, SCs generate fusion-competent myoblasts and can
self-renew at least to a limited extent. Any interruption in the proliferation or fusion of myo‐
blasts, or any alterations in the extracellular matrix leads to the development of fibrosis,
compromising the establishment of the correct muscular function [8, 10]. Proliferative MyoD
and/or Myf5 positive myogenic cells are termed myoblasts. Both SCs and myoblasts increase
their cytoplasmic-nuclear ratio and can migrate along myofibers. Proliferating myoblasts
withdraw from the cell cycle to become terminally differentiated myocytes that express the
“late” myogenic regulatory factors (MRFs), Myogenin and MRF4, and subsequently muscle-
specific genes such as MHC and muscle creatine kinase (CKM), and stopping Pax7 expres‐
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sion. Myogenic subpopulations have also been identified by their enriched M-cadherin and
CD34 expression. M-cadherin can be considered to be a reliable marker for both quiescent
and activated SCs. Once fusion of myogenic cells is completed, newly formed myofibers in‐
crease in size and myonuclei move to the periphery of the muscle fiber [1, 10, 13].
2.2.3. Degeneration
This scenario changes dramatically when the muscle is damaged, in which muscle degener‐
ation after acute injury is characterized by myofiber necrosis and is followed by inflamma‐
tion, tissue reconstruction and remodeling [10]. The necrosis is triggered by disruption of
the myofiber sarcolemma resulting in increased myofiber permeability. The disruption of
myofiber integrity is reflected by increased serum levels of muscle proteins, such as CK
(usually restricted to the myofiber cytosol) [1]. It has been hypothesized that increased Ca2+
influx after sarcolemmal or sarcoplasmic reticulum damage results in a loss of Ca2+ homeo‐
stasis and increased Ca2+-dependent proteolysis that drives tissue degeneration resulting in
focal or total autolysis depending on the extent of the injury [1].
2.2.4. Inflammation
The early regenerative response in skeletal muscle is similar to that in other tissues and requires
the coordinated regulation of inflammation, extracellular matrix remodeling, and myofiber
growth [14]. The early phase of muscle injury is usually accompanied by the activation of
mononucleated cells, mainly inflammatory cells and myogenic cells. Factors released by the
injured muscle activate inflammatory cells residing within the muscle, which in turn pro‐
vide the chemotactic signals to circulating immune cells. Neutrophils are the first immune
cells to invade the injured muscle,  with a significant increase in their number being ob‐
served as early as 1–6h after myotoxin or exercise-induced muscle damage. After neutrophil
infiltration and 48h post-injury, macrophages become the predominant inflammatory cell type
within the site of injury. Macrophages infiltrate the injured site and through phagocytosis
remove cellular debris and may affect other aspects of muscle regeneration by activating
myogenic cells [1]. Testosterone has a documented ability to modulate the activity of im‐
mune, fibroblast, and myogenic precursor cells, which are all components of regeneration [14].
3. Skeletal muscle injury models
In order to study the process of muscle regeneration in a controlled and reproducible way, it
was necessary to develop experimental models of muscle injury [1]. In this sense, a variety
of experimental models that compromise skeletal muscle function or destroy this tissue is
available. Each of the injury models can potentially have a different effect on the fate of resi‐
dent cells and circulating cells within the muscle bed after the trauma [10]. A large number
of studies, involving a variety of experimental injuries, such as injection of myotoxic agents,
crush, ischemia, denervation and muscular dystrophies, demonstrate the unique ability of
skeletal muscle for regeneration, irrespectively the precise method used to induce the initial
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injury [15]. In this review we will focus on chemical and mechanical models of skeletal mus‐
cle injury, adding a new model of muscle injury based on surgical myectomy, developed in
order to mimic severe losses of skeletal muscle mass. Other models, like exercise and dener‐
vation, will also be outlined. The latter is not a model of injury but else of skeletal muscle
disuse but that also can be used to investigate skeletal muscle remodeling. There is a variety
of other genetic models that are essential in studying diseases like Duchenne muscle dystro‐
phy (Mdx mouse is currently the most widely used in this case) but will not be discussed in
this review.
3.1. Chemical methods of skeletal muscle injury
The use of myotoxins, such as bupivacaine (Marcaine), cardiotoxin (CTX), and notexin
(NTX) is perhaps the easiest and most reproducible way to induce muscle injury and regen‐
eration. Myotoxins are also widely used to induce skeletal muscle injury because their inoc‐
ulation by intramuscular injection does not require complex surgery. Several chemical
agents are known to produce skeletal muscle damage. Severe muscle fiber damage, like
breakdown of sarcolemma and myofibrils, has been described after intramuscular injections
of 0.75% bupivacaine, 2% mepivacaine, or 2% lidocaine associated to epinephrine [18].
While lidocaine can cause rapid destruction of skeletal muscle fibers, long-acting anesthet‐
ics, like bupivacaine, are more often used to cause skeletal muscle injury in rodents [19].
3.1.1. Bupivacaine
The bupivacaine injection procedure is simple and quick, does not involve extensive sur‐
gery, and induces a regeneration process which is qualitatively similar to that observed in
other model systems. Doses of 1.5 and 1% wt/vol produce significant levels of muscle injury
and subsequent regeneration, but these doses also produce large regions of ischemic muscle
tissue. Doses of 0.75 and 0.5% bupivacaine are also effective in inducing regeneration and
produce little or no ischemia [16]. Muscle fiber necrosis is extremely rapid after induced bu‐
pivacaine injury [14]. Injection of the drug into small skeletal muscles of rat or mouse leads
to immediate and massive myonecrosis followed by phagocytosis of necrotic debris and a
rapid and apparently complete regeneration of muscle fibers 3-4 wk after injection. The peak
isometric twitch and tetanic tensions produced by rat fast-twitch extensor digitorum longus
muscle injected with bupivacaine returns to normal values by 21 d after injection [17]. Mor‐
phological analysis has shown that many indexes of successful regeneration in healthy mus‐
cle can be completed within 2–3 weeks of recovery from injury [14]. The sequence of fiber
breakdown induced by bupivacaine is similar to that of progressive muscular dystrophy
[18] and it is also striking that the same types of muscle fibers are spared by both Duch‐
enne’s muscular dystrophy and bupivacaine toxicity. It has been suggested that bupivacaine
may disrupt Ca2+ homeostasis in vivo, triggering Ca2+-activated cellular death pathways that
include proteolysis. This suggestion is supported by the findings that
i. bupivacaine affects sarcoplasmic reticulum function in vitro,
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ii. extracellular Ca2+ omission delays the morphological changes and decreases the
protein degradation rate that are observed in isolated rat soleus muscle exposed to
bupivacaine, and
iii. bupivacaine uncouples isolated rat liver and heart mitochondria and decreases mi‐
tochondrial membrane potential and oxygen consumption both in cultured fibro‐
blasts and Ehrlich tumor cells [19].
Extracellular Ca2+ plays a part in mediating the muscle damage caused by bupivacaine but
other factors must also be involved [20]. For example macrophage invasion is necessary for
complete degeneration of myofibrillar components [21]. Saito and Nonaka [22] injected
0,5ml of 0,5% bupivacaine after soleus muscle exposure of Wistar rats, and observed that SCs
proliferation began at almost the same time as following muscle crush injuries. Bupivacaine
is still commonly used for the purpose of studying the mechanisms of skeletal muscle regen‐
eration following injury [7, 14, 15, 22].
3.1.2. Cardiotoxin and Notexin
Snake venom is known for a long time to directly affect the skeletal muscle, producing fibril‐
lation, contractures and depolarization of the sarcolemma. Although initially ascribed to the
phospholipase A content of this venom, muscle contracture and depolarization seem to be
related to the cardiotoxic action of cobra venom [23]. Notexin (NTX) is a phospholipase A2
neurotoxin peptide extracted from snake venoms that blocks neuromuscular transmission
by inhibition of acetylcholine release. Cardiotoxin (CTX) is also a peptide isolated from
snake venoms, but it is a protein kinase C-specific inhibitor that appears to induce the depo‐
larization and contraction of muscle cells, disruption of membrane structure, and lysis of
various cell types [1]. CTX is postulated to be neurotoxic as its injection destroys neuromus‐
cular junctions [24]. However, CTX might cause direct destruction of muscle tissues [25].
Snake CTX polypeptide is now known to be a potent inducer of muscle contracture with
phospholipase A likely acting in accelerating the action of CTX rather than in augmenting it
[23, 26]. Dantrolene antagonizes CTX-induced contractures, suggesting a role for Ca2+ de‐
rived from the sarcoplasmic reticulum in CTX action. CTX rapidly lowers the threshold for
Ca2+-induced Ca2+ release in heavy sarcoplasmic reticulum fractions. The mechanism of ac‐
tion involved in contractures of skeletal muscle appears to be related to the immediate and
specific effect of CTX (Ca2+ release by the sarcoplasmic reticulum) [27, 28].
A more recent study by Gutiérrez and Ownby [25] focused on the role of PLA2 as important
myotoxic components in these venoms suggesting that myotoxic PLA2s binds to acceptors in
the plasma membrane leading to its disruption and pronounced Ca2+ influx which, in turn,
initiates a complex series of degenerative events associated with contracture, activation of
calpains and cytosolic Ca2+-dependent PLA2s, and mitochondrial Ca2+ overload. Fourie et al.
[30] already had suggested that the biological effects of CTX could be a consequence of in‐
hibition of plasma membrane (Ca2+ + Mg2+)-ATPases. The local myonecrosis is often associat‐
ed with other effects, such as hemorrhage, blistering and edema, in a complex pattern of
local tissue damage. Apart from membrane-active CTXs, snake venom hemorrhagic metallo‐
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proteinases also cause myonecrosis, but the mechanism involved is likely to be an indirect
one, probably related to ischemia [25]. CTX is a useful model for muscle regeneration that
does not influence muscle architecture like basal lamina or microvasculature, making the re‐
generation process less complicated than other models like crush, where for example, inade‐
quate blood supply might result in an increase of fibrosis. CTX injection also results in faster
and more extensive muscle degeneration, and an earlier start of the reconstruction phase,
than muscle crushing [24].
3.2. Mechanical methods of skeletal muscle injury
Crush injuries of the skeletal muscle can occur in considerable numbers following natural
disasters  or  acts  of  war and terrorism.  They can also occur sporadically  after  industrial
accidents or following periods of unconsciousness from drug intoxication, anesthesia, trau‐
ma or cerebral events [31]. Crushing as a method of inducing muscle injury and regenera‐
tion was first described by Bassaglia and Gautron [32], and has since been used in several
published research studies [24]. Muscle damage occurs at three distinct stages: at the time
of the initial mechanical crushing force, during the period of ischemia and during the peri‐
od of reperfusion [31]. It has been hypothesized that ischemia is the primary instigator of
local muscle damage following crush injuries [33]. However, studies have shown that al‐
though skeletal muscle tissue can survive circulatory ischemia for 4h, the mechanical force
sustained in crushing, along with ischemia, causes skeletal muscle death in only 1 h. Stud‐
ies of enzyme release suggest that most damage to myocytes occurs during the reperfu‐
sion stage rather than the ischemic stage [31]. Animal models of muscle injury should closely
mimic the clinical situation. Among these models open crush lesion have been used frequent‐
ly, allowing standardized evaluation of regeneration in a selected muscle. For application
of the trauma, either forceps or custom-made devices have been used. There are two types
of muscle-crush models described in the literature: the segmental crush and the complete
crush, where only 4-6% of the fibers remain intact [34]. There are different forms to accom‐
plish the segmental  crush model but most  of  them include the use of  a  surgical  instru‐
ment (hemostatic clamp e.g.) to produce a standardized closing force in a specific area of a
muscle  causing a  compression contusion injury [35].  One of  the  important  steps  of  this
procedure is denervation, which makes the initial steps of regeneration less painful for the
animal.  Skeletal  muscle contusion can also be performed without skin incision by drop‐
ping a mass over a selected muscle. This technique was used by Iwata, Fuchioka [36] em‐
ploying a 640g mass dropped from a 25 cm height onto an impactor (diameter 10 mm)
placed on the belly of the rat medial gastrocnemius. This procedure damaged around 47%
of the entire cross-sectional area of both medial and lateral gastrocnemius.  At day 2 post-
injury, an intense inflammatory response and necrotized myofibers with infiltrated mono‐
nuclear cells were observed. No myotubes were found at this stage. However, a number of
regenerative myotubes were detected at days 7, 14, and 21 days post-injury. This study also
showed that normal locomotion recovers prior to isometric force and complete regenera‐
tion of the injured muscle [36]. The main disadvantage of the complete muscle crush is the
potential damaging of myoneural junctions which triggers not only regeneration of mus‐
cle substance but also initial  innervation deficits.  These deficits  always lead to impaired
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healing [34]. Histological analysis of muscle regeneration after crush injury shows an ini‐
tial phase of inflammation followed by SCs activation, myotube regeneration and fibrosis
of the muscle.  It  has been shown that development of fibrotic tissue is  one of the main
factors affecting the recovery of muscle function after traumatic muscle injury [34].  In a
qualitative assessment performed by our group we tested the open crush lesion in the tibialis
anterior  (TA) muscle of adult Sasco Sprague rats. Different standardized force intensities,
durations of muscle compression (30 seconds and 1 minute) and time points (3, 8, 15 and
21 days post-surgery)  were considered for  the histological  evaluation of  skeletal  muscle
injury.  Hematoxilin-eosin  (HE)  and Masson’s  trichrome staining  were  employed in  this
preliminary study. At day 3 post-surgery, myofiber damage was evident and the lymph
nodes were reactive due to the active inflammatory process. The presence of fibrosis was
evident only following 15 days from the initial  injury.  This evaluation revealed that the
crush model was not the most appropriate for in vivo  evaluation of cellular therapies for
skeletal  muscle regeneration aid,  since the extent of this injury type did not present the
magnitude required to accurately appreciate the biological effects of MSCs utilization [38].
3.3. Myectomy and myotomy
The loss of a portion of a skeletal muscle poses a unique challenge for regeneration of mus‐
cle tissue and restoration of its normal structure and function [39]. In the event of large-scale
soft tissue traumas, extensive loss of full-thickness native tissue architecture renders the
wound site unable to support normal regeneration process. In severe tissue injuries the
acute inflammatory response is followed by formation of a provisional fibrin matrix derived
from trauma-associated blood clotting and this matrix is then infiltrated by type I collagen-
producing fibroblasts [40]. In order to mimic those situations, new experimental models
have been developed in which a defined portion of the muscle tissue is removed, creating a
myectomy defect within the muscle. For example, Merrit et al. [39] removed a 0.5 x 1.0 cm or
a 1.0 x 1.0 cm fraction of the gastrocnemius muscle of rats, creating a small and large defect
respectively. This was accomplished lacerating the lateral side of the muscle with a #9 scal‐
pel blade. We have recently developed a novel experimental muscle injury model in the TA
muscle of adult Sasco Sprague rat, by using a biopsy punch to create a standardized myecto‐
my defect. Sasco Sprague male rats with 250-300g were used and after a standardized 5 mm
diameter myectomy lesion in the mid-belly of the tibialis anterior muscle, the defect was com‐
pletely filled with different vehicles and/or biomaterials, cellular suspensions containing
1x106 human MSCs isolated from Wharton’s jelly and conditioned media (Figure 1). This
concentrated media contains trophic factors secreted by MSCs during cell culture. In our re‐
search work, the myectomy model proved to be the most appropriate for a comprehensive
and standard evaluation of the rat skeletal muscular regeneration ability. The regeneration
process in other models of lesion, like simple muscle crush, did not present the magnitude
required to accurately appreciate the biological effects of MSCs [38].
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Figure 1. Biopsy punch for myectomy lesion creating a 5 mm Ø defect in the rat tibialis anterior (TA) muscle.
Another less invasive model of muscle injury has been used in a number of studies by pro‐
ducing a laceration injury (myotomy) [42-44]. In some cases this was obtained by a partial
thickness (50%) cut of gastrocnemius muscles in mice at 60% of their length from their distal
insertion, through 75% of their width and then sutured with a modified Kessler stitch and
simple sutures using a PDS 7.0 wire (Ethicon, Somerville, New Jersey) [43]. Other studies
used a full-thickness (100%) cut though 50% of the gastrocnemius muscle width [44]. The ad‐
vantages of this model are its reproducibility and the ability to apply consistently precise in‐
jections into the laceration site [43].
3.4. Denervation (indirect model)
Innervation regulates skeletal muscle mass and muscle phenotype and peripheral nerve in‐
jury in the rat is a widely used model to investigate nerve regeneration and can also be em‐
ployed as a model of muscle inactivity and muscle atrophy. Changes in the muscles may
contribute to functional deficit after nerve injury [47]. Denervation induces muscle atrophy
and 25 months post denervation muscle fibers cross sectional area of the extensor digitorium
longus (EDL) muscle diminish to only 2.5% of control animals although their fascicular or‐
ganization is maintained [47]. The effect of denervation on muscle atrophy is both activity-
dependent and activity-independent since the degree of hindlimb muscle atrophy after
spinal isolation (activity-independent nerve influence) is less when compared to the atrophy
caused by removal of all nerve influences by transecting the sciatic nerve [9]. Two basic
mechanisms are responsible for denervation-induced muscle atrophy. First, there is aug‐
mented activity of the ubiquitin-proteasome pathway and proteolysis [48]. Second, there is
cell death and myonuclei apoptosis conjugated with decreased capacity of satellite cell-de‐
pendent reparative myogenesis [49]. Together with atrophy, denervated/reinnervated mus‐
cles undergo phenotypical changes and conversion between muscle fiber types [50]. The
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relative increase in type I or type II muscle fibers following denervation seems to depend on
the type of muscle fibers predominant in the muscle, with type II muscle fibers (fast fibers)
increasing in proportion in soleus (considered a slow muscle) and type I muscle fiber num‐
ber increasing in gastrocnemius and TA muscles [51]. Likewise, the degree of muscle fiber
atrophy in short-term denervation (4 weeks) has been noticed to be greater in the muscle fi‐
ber type that is more abundant in the affected muscles [52]. Earlier studies suggested that it
was possible that denervated muscles could have increased muscle plasticity due to acceler‐
ation in the early myoblastic stages of muscle regeneration. Nevertheless McGeachie and
Grounds [53] data proved that very few precursors were proliferating in denervated muscle
within 30 h after injury, and the onset of myogenesis at 30 h was essentially the same in de‐
nervated and innervated muscle. They compared the onset of DNA synthesis in muscle pre‐
cursors in denervated and innervated muscle of adult BALBc mice regenerating after a
simple cut injury. This study concluded that although denervation of skeletal muscles caus‐
es an increase in SCs and connective tissue cell turnover, it does not “prime” the general
population of muscle precursors to start synthesizing DNA more rapidly after injury than in
innervated muscle [53]. After sciatic nerve transection at an adult age, electromyography
(EMG) patterns in hindlimb muscles during locomotion remained highly abnormal even af‐
ter recovery periods lasting 15 or 21 weeks [54]. This may be a limitation when using dener‐
vated muscles as a model of muscle injury since regeneration might be affected for a very
prolonged period. Like already mentioned, other models of skeletal muscle injury, like com‐
plete crush or myectomy, can be accompanied by denervation since these traumatic models
may possibly damage peripheral nerves or myoneural junctions. This might also be an un‐
desirable occurrence in the standardization of these models of muscle injury. In fact, our
preliminary work using TA myectomy showed that few animals developed severe muscle
force deficit after 4 weeks recovery, suggesting that damaged of the supplying nerve occur‐
red in these animals subset.
In our research group, standard peripheral nerve injuries in the rat sciatic nerve model have
been performed [57-63] in order to evaluate different therapeutic approaches including sev‐
eral biomaterials and cellular systems to promote sensitive and functional recovery of the
nerve. A standard crush injury is performed by a non-serrated clamp (Institute of Industrial
Electronic and Material Sciences, University of Technology, Vienna, Austria), exerting a con‐
stant force of 54 N for a period of 30s, 10mm above the bifurcation into tibial and common
peroneal nerves, inducing a 3mm axonotmesis lesion [57-63]. In order to induce a standard
neurotmesis lesion in the rat sciatic nerve model, considered a more serious lesion, under
deep anaesthesia, the right sciatic nerve is exposed through a skin incision extending from
the greater trochanter to the distal mid-half followed by a muscle splitting incision. After
nerve mobilisation, a transection injury is performed (neurotmesis) using straight microsur‐
gical scissors. The nerve is injured at a level as low as possible, in general, immediately
above the terminal nerve ramification. To prevent autotomy, a deterrent substance should
be daily applied to rat right foot [57-63]. Both experimental injuries induce severe motor def‐
icit and loss of sensory function, evaluated by measuring extensor postural thrust (EPT) and
withdrawal reflex latency (WRL), respectively [57-63]. Sensory and motor deficit then pro‐
gressively decreased along the post-operative, depending on the therapeutic approach used.
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Very promising results were obtained with chitosan type III membranes and MSCs isolated
from the umbilical cord matrix. In addition, we also perform kinematic analysis of the rat
walk which is a more sensitive behavioral test. This analysis is increasingly being used to
assess functional recovery in peripheral nerve research because of its higher accuracy and
better relationship with histological outcome [57-63]. We should bare in mind that locomo‐
tion is also of higher functional relevance since it involves integrated function of both the
motor and sensory systems and their respective components, such as skeletal muscles, sen‐
sory endings, efferent and afferent nerve fibers and integrative centers within the central
nervous system. Muscles innervated by sciatic nerve branches include both dorsiflexors and
plantarflexors and, although in our published studies we focused our kinematic analysis on‐
ly in the stance phase, we now prefer to include analysis of the ankle joint motion also dur‐
ing the swing phase in order to provide additional information [59]. Denervation can be a
very useful model of skeletal muscle injury for some experimental studies but some limita‐
tions might be pointed out in studies that attempt to focus exclusively on the muscular re‐
generation process. Nevertheless and as demonstrated by several studies, this muscular
regeneration process is highly dependent of the neural supply and the nerve regeneration
itself can be influenced by the damaged muscle tissue.
4. Tissue engineering and regenerative medicine
Every day thousands of clinical procedures are performed to replace or repair tissues in the
human body that have been damaged through disease or trauma that use tissue engineering
technology. The use of constructs for tissue engineering (TE) and regenerative medicine are
promising innovative therapies that can address several clinical situations. These constructs
are often combination of cells, scaffolds and biological factors. Although there are only a few
commercial products currently in the market for cell/drug delivery, probably because each
type of cell requires its own specific encapsulating microenvironment with cell-specific ma‐
terial properties and spatially controlled bioactive features, a vast amount of research is be‐
ing performed worldwide on all aspects of tissue engineering/regenerative medicine
exploring polymer materials. To implant cells into defective skeletal muscles, there are two
main techniques. The cellular system may be directly injected into the scaffold which is lo‐
calized in the injury site. It can also be performed by pre-adding the cells to the scaffold via
injection or co-culture (in most of the cellular systems, cells are allowed to form a monolay‐
er) and then the biomaterial with the cellular system is implanted in the injured muscle. In
case of multiple sites of injury, the systemic administration of cells capable of reaching dam‐
aged tissues would be an interesting alternative [64].
4.1. – Scaffolds and Biomaterials
Scaffolds, which are used to deliver cells, drugs, and genes into the body, can take on vari‐
ous forms from porous solid devices to injectable networks, such as a typical three-dimen‐
sional porous matrix, a nanofibrous matrix, a hydrogel, and microspheres. Although solid
scaffold provide a mechanically strong matrix for seeded cells, hydrogel scaffolds and mi‐
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crospheres are becoming increasingly popular in TE. The spherical nature maximizes the
surface area, and the small volume of beads facilitating biomolecular transport. Regarding
hydrogels, they have a similar microstructure to the extracellular matrix (ECM) and allow
good physical integration into the defect by the use of minimally invasive approaches for
material and cell/drug delivery. The biological, chemical, topography features and mechani‐
cal properties, as well as the degradation kinetics of hydrogels, can be tailored depending on
the application [65-68]. Aligned nanoscale and microscale topographic features in scaffolds
have been also reported to influence the alignment of cells. For example, this alignment is an
important requirement of functional skeletal muscle since it leads to alignment of myoblasts
and cytoskeletal proteins and promote myotube assembly along the nanofibres and micro‐
grooves to mimic the myotube organization in muscle fibres [65, 68-70]. Scaffolds are used
successfully in various fields of tissue engineering such as bone formation, periodontal re‐
generation, cartilage development, as artificial corneas, in tendon repair and in ligament re‐
placement. In addition, the incorporation of drugs (i.e., inflammatory inhibitors and/or
antibiotics) into scaffolds or specific molecules to provide adequate signals to the cells is also
possible [71] Depending on the medical applications, scaffolds requirements will depend on
its function. Hydrogels can be used as a physical barrier to protect the cells from hostile ex‐
trinsic factors before delivery, or be used as a matrix to drug controlled release or cell adhe‐
sion, growth and differentiation to further improve the secretion of therapeutic proteins
from cells. In fact cells are capable of delivering drugs in response to an external stimulus,
which is highly advantageous to maintain homeostasis for patients suffering from chronic
diseases. For the first application, the scaffold needs:
i. to be biocompatible, by minimizing the patients’ immune response, which is detri‐
mental to cell viability, hydrogel stability, and mass transport. Ideally, the scaffold
should evoke no or only minimal fibrous tissue reaction, macrophage activation,
and cytokine and cytotoxic agent release
ii. to have controllable degradability, being the degradation products not toxic and
eliminated easily from the implantation site by the body, and
iii. to have mechanical properties that are sufficient to shield cells from tensile forces
without inhibiting biomechanical cues to cells through mechanotransduction path‐
ways that mediate tissue homeostasis, morphogenesis, cell growth, contractility,
differentiation, and pathophysiology [70-72].
For the second applications further requirements are needed, mainly:
i. a microstructure that allows for the influx of nutrients and oxygen toward the en‐
capsulated cells and prevents the efflux of therapeutic molecules and cellular
wastes away from the scaffold; this is assured through adequate pore size distribu‐
tion and its interconnectivity. A high surface:volume ratio should be suitable for
cell/drug attachment;
ii. adequate drug binding affinity to allow a controllable drug released to be stable
when incorporated in the scaffold at a physiological conditions;
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iii. bioadhesion, to allows cells and tissues to adhere to scaffolds. Some hydrogels such
as fibrin or collagen inherently exhibit bioadhesive properties, but others do not
and therefore linker molecules that enable covalent or non-covalent molecular in‐
teractions between the scaffold and its surroundings are incorporated;
iv. the mechanical properties of the scaffold, commonly controlled with the polymer
concentration and molar ratio between polymers and cross-linking molecules,
should match those of the tissue at the implantation site as well as the degradation
rate that should match the rate of tissue regeneration [73-77].
4.1.1. Hydrogel scaffolds
Hydrogels, three-dimensional (3D) networks of hydrophilic polymers, are appealing for bio‐
logical applications because of their high water content, high permeability, biocompatibility,
and the ability of be placed into critical defects in a minimally invasive manner [78]. They
are being used in a wide range of tissues, including cartilage, bone, muscle, fat, liver, and
neurons. For use in drug/cell delivery, hydrogels should be low-viscosity solutions prior to
gelling, which is crucial to maintain cell viability during the encapsulation process, and
should rapidly gel in the human body. These properties can be fine-tuned through varia‐
tions in the chemical structure and cross-linking density in hydrogels. Injectable hydrogels
can be formed in situ by either chemical or physical cross-linking methods [79, 80]. Physical
cross-linked hydrogels are capable of phase transition in response to external stimuli such as
temperature, pH or both [81]. Chemically cross-linked hydrogels are prepared through pho‐
topolymerization, disulfide bond formation, or reaction between thiols and acrylate or sul‐
fone. The latter hydrogels undergo significant volume changes compared to the first ones
[81-83]. The pH/temperature-sensitive hydrogels show several advantages over thermo-sen‐
sitive ones, such as the absence of clogging during injection and avoidance of pH decreased
caused by degradation. The pH/temperature-sensitive copolymer hydrogels can be pre‐
pared by combining a pH-sensitive moiety with a temperature-sensitive block. For example,
if acidic sulfamethazine oligomers (OSMs) are coupled with thermosensitive poly(e-CL-co-
LA)-PEG-poly-(e-CL-co-LA) triblock copolymers a pH/temperature-sensitive hydrogels
(OSM-PCLA-PEG-PCLA-OSM) is produced. Photopolymerized hydrogel systems have been
reported to provide better temporal and spatial control over the gelation process [79, 81, 84].
4.1.2. Biomaterials for scaffold fabrication
A wide variety of natural and synthetic materials have been used to prepare injectable hy‐
drogels. Natural polymers, which are either components of or have macromolecular proper‐
ties similar to the natural ECMs, are known to often undergo rapid degradation upon
contact with body fluids or medium and show batch-to-batch variation. Synthetic hydrogels
offer improved control of the matrix architecture and chemical composition, no immunoge‐
nicity, consistent supply of large quantities, but tend to have lower biological activity.
Therefore, modification of natural and synthetic derived hydrogels is usually required [79].
A natural biodegradable 3D scaffold can be made of acellular muscle ECM but it’s fragile
and difficult to handle [85]. Another natural biodegradable scaffold can be created by using
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fibrin, which leads to a process much similar to wound healing, in which fibrin forms a tem‐
porary scaffold to serve tissue regeneration and then is replaced by the physiological ECM.
Fibrin has the additional advantage that it binds growth factors [70].
Fibrin hydrogels are made from commercially purified allogeneic fibrinogen and purified
thrombin, and have been used in a variety of tissue engineering applications. Its main disad‐
vantages reported to be shrinkage of the gel, low mechanical stiffness and its rapid degrada‐
tion can be overcome by incorporating other polymers such as gelatin, hyaluronic acid, and
chondroitin-6-sulfate. Fibrin glue is clearly distinguished from fibrin hydrogels that are pre‐
pared from purified fibrinogen and thrombin. Despite the commercial fibrin glue is availa‐
ble in standardized quality; autologous fibrin glue is cheaper and has no viral transmission
and prion infection [86]. Tisseel® VH, is a fibrin glue commercialized by Baxter, and consists
of a two-component fibrin biomatrix with highly concentrated human fibrinogen to produce
fibrin gel from a blood sample and is safe to be used in TE. FloSeal® is another commercial
hemostatic matrix with potential in TE, and consists of a cross-linked bovine-derived Gela‐
tin Matrix component and a human-derived Thrombin component. Literature reports that
myoblasts seeded on fibrin gels have been shown to differentiate into contracting muscle fi‐
bres and to demonstrate a normal length–tension and force–frequency relationship [87, 88].
Alginate is the designation given to a natural family of biodegradable, biocompatible, hy‐
drophilic and non-toxic polysaccharides extracted from some marine algae and some micro‐
organisms. Alginates are linear block co-polymers composed of two different monomers, β-
D-mannuronic acid (M) and α-L-glucuronic acid (G), which are linked by (1-4) glycosidic
bonds. The main property of alginate that potentiates its use in different areas, it is its ability
to bind some divalent cations such as Ca2+ in the carboxylic groups which provides the ge‐
lation of the alginate solution. The properties of the gel are dependent of the ratio between
M and G monomers (M:G ratio); if the proportion of the G monomer is predominant, a
strong brittle gel it obtained, whereas if the proportion of the M monomer is predominant,
the formed gel will be weaker, but more flexible, because there are less junction zones be‐
tween the polymer chains. As alginate is a polyelectrolyte, more specifically a polyanion, it
can be ionically associated with a polycation existent in the same solution through hydrogen
bonding or electrostatic interactions, forming a polyelectrolyte complex [89, 90]. Cell-encap‐
sulating calcium cross-linked alginate hydrogels have been extensively studied because algi‐
nate molecules are anionic polysaccharides and do not associate with many proteins. Since
alginate itself is inert for cell attachment and spreading, the cell adhesion properties can be
tailored by linking molecules such as RGD peptides to its backbone [91].
Chitosan is a natural and hydrophilic copolymer, and it is composed by two monomeric
units, D-glucosamine and N-acetyl-D-glucosamine linked by β(1–4)-glycosidic bond. This
linear polysaccharide has been widely studied in medical applications due to its biocompati‐
bility, biodegradability, non-toxicity, fungistaticity, antimicrobial activity, non-carcinogenic‐
ity, notable affinity to proteins, promotion of cell adhesion as well as proliferation and
differentiation [67]. Chitosan results from the alkaline deacetylation of the chitin and its sol‐
ubility is mainly influenced by its molecular weight and degree of deacetylation. Some
methods have been developed to lower the molecular weight of chitosan by hydrolysis of
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the polymeric chains, in order to produce chitosan salts which are soluble in water. Chito‐
san-based hydrogels have been gelled via glutaraldehyde cross-linking, UV irradiation, and
thermal variations [81].
Hyaluronic Acid (HA) is a natural, hydrophilic and non-sulfated glycosaminoglycan. This
polymer is a linear polysaccharide, in which the repeating unity is a disaccharide composed
by two monomers, D-glucuronic acid and N-acetyl-D-glucosamine, linked through alternat‐
ing β1,3 and β1,4 glycosidic bonds. HA has been used as a biomaterial in various medical
applications, due to its biocompatibility, biodegradability, and non-immunogenicity. HA is
the main component existent in the extracellular matrix (ECM) of living tissues, namely in
the connective, epithelial and neural. This polymer, due to its structural and biological prop‐
erties, has the ability of mediate the cell signalling and behaviour, and the matrix organiza‐
tion. HA is able of interact with some cell surface receptors, being involved in the tissue
hydrodynamics, cell migration and proliferation. Several strategies have been reported to
prepare HA-based hydrogels [92, 93].
Among the most widely used synthetic polymers for scaffolds, either alone or copolymer‐
ized with synthetic or natural polymers, as biodegradable polymers are polyglycolide, poly‐
lactide and its copolymer poly(lactide-co-glycolide), polyphosphazene, polyanhydride,
poly(propylene fumarate), polycyanoacrylate, polycaprolactone, polydioxanone, and poly‐
urethanes, and as non-biodegradeable polymers are included polyvinyl alcohol (PVA), poly‐
hydroxyethymethacrylate, and poly(N-isopropylacrylamide) [71, 94].
The majority of natural biomaterials used in clinical applications are derived from animal or
human cadavers’ sources. In spite of thorough purification methods, these materials bear
the inherent risk of transfer viral diseases and may cause immunological body reactions
while synthetic biomaterials are not associated with these risks. So, a critical issue in this
type of cellular transplants is the search for an optimal vehicle to provide the ideal environ‐
ment for cell hosting and for the release and conduction of molecules to the site of injury for
cell-host interaction. Taking this into account we evaluated different biomaterials as vehicles
for the cellular system intended to be tested for skeletal muscle regeneration using our
myectomy injury model in the rat. Plasma derived substances, hemostatic matrix solutions
and hydrogels (Figure 2 and Figure 3) were tested and the in vivo response was compared
histologically according to the International Standard ISO 10993-6 (see 5.1.3). The following
procedure was done under sterile conditions. For preparation of the spherical hydrogel, the
polymer solution is prepared by adding in a ratio of 1:1 (V/V), a sodium alginate aqueous
solution 7% (m/V) to a sodium hyaluronate aqueous solution 0.5% (m/V), under magnetic
stirring. Afterwards the polymer solution is inserted into an insulin syringe and a droplet is
released into an excess of cerium nitrate solution 135mM, in order to obtain a cross-linked
polymer sphere of approximately 60 µl of volume. Cerium nitrate and sodium hyaluronate
solution were sterilized by microfiltration (0.22 µm membrane) and sodium alginate powder
is sterilized in an autoclave (120ºC for 15 minutes) previous to the solution preparation (Fig‐
ure 2 and Figure 3). These tested biomaterials including the spherical hydrogel were not on‐
ly used as vehicles but their properties were also evaluated and optimized to find a suitable
matrix for the cellular implants.
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Figure 2. Hydrogel preparation (alginate, hyaluronic acid and cerium).
Figure 3. Application of a spherical hydrogel containing 1x106 MSCs from the Wharton’s jelly, in the 5 mm Ø TA myec‐
tomy defect.
4.2. Cells
There is evidence both from animal studies and clinical investigations that cell therapy in‐
volving different types of stem cells application is promising as means to promote regenera‐
tion of skeletal muscles following severe injuries. Technical or/and ethical difficulties in
obtaining sufficient and appropriate stem cells from the bone marrow or from embryos (ob‐
tained from assisted reproduction techniques or somatic nuclear transfer - cloning) have
limited the application of this type of therapy. Stem cells are known as an undifferentiated
Biomaterials and Stem Cell Therapies for Injuries Associated to Skeletal Muscular Tissues
http://dx.doi.org/10.5772/ 53335
345
population, with endless self-renewal and sustained proliferation in vitro and multilineage
differentiation ability [95]. The in vitro multilineage differentiation is the concept that gives
these cells an extreme priority for use in tissue and cell-based therapies. Stem cells can be
loosely classified into 3 categories based on their functional role: hematopoietic stem cells,
mesenchymal stem cells (MSCs) and embryonic stem cells [95].
MSCs have become one of the most exciting targets for tissue regeneration due to their high
plasticity, proliferative and multilineage differentiation capacity. These cells are capable of
differentiating into adipose, bone cartilage and muscle. Among all this notable characteris‐
tics, MSCs reveal other properties of great importance, they present low immunogenicity
and high immunosuppressive properties due to a decreased or even absence HLA Class II
expression [96]. Differentiation potential of MSCs in multilineage end-stage cells has been
proven, so as the treatment potential in musculoskeletal disorders [97, 98]. Since their first
isolation in 1968, from rat bone marrow [99], MSCs have been isolated with success from al‐
most all tissue sources: skeletal muscle, adipose tissues, synovial membranes, umbilical cord
matrix and blood, placental tissue, amniotic fluid among others. Along with differentiation
capacity, an increasing amount of data has demonstrated that the MSCs have the capacity of
modulating the surrounding environment, by secretion of multiple factors and activation of
endogenous progenitor cells [100, 101].
4.2.1. Umbilical cord
From our data and from previously published experimental work, the development of cell
therapies associated to biomaterials is a promising tool for increase skeletal muscle regener‐
ation, avoiding the irreversible loss of function and limit the fibrous scar tissue presence
[57-59]. Recent years have witnessed an explosion in the number of adult stem cells popula‐
tions isolated and characterized. While still multipotent, adult stem cells have long been
considered restricted, giving rise only to progeny of their resident tissues. Recently, and cur‐
rently controversial studies have challenged this dogma, suggesting that adult stem cells
may be far more plastic than previously appreciated [102, 103]. Extra-embryonic tissues as
stem cell reservoirs offer many advantages over both embryonic and adult stem cell sources.
The umbilical cord matrix is an important and safe source of MSCs with positive effects in
nerve and skeletal muscle regeneration, with no ethical or technical issues. MSC isolated
from umbilical cord matrix (Wharton’s jelly), as well as embryonic stem cells (ESCs) are ori‐
ginated from inner cell mass of blastocyst [104]. Comparing with ESCs, MSCs have shorter
population doubling time; can be easily cultured in plastic flasks, are well tolerated by im‐
mune system; therefore transplantation of these cells into non-immune-suppressed animals
does not induce acute rejection. Most important, these cells do not originate teratomas [104].
Like bone marrow stromal cells and other MSCs, the MSCs from the Wharton’s jelly are
plastic adherent, stain positively for markers of the mesenchymal lineage (CD10, CD13,
CD29, CD44, CD90, and CD105) and negatively for markers of the hematopoietic lineage.
These MSCs are capable of self-renewal with sustained proliferation in vitro and can differ‐
entiate into multiple mesodermal cells. The high plasticity and low immunogenicity of these
cells turn them into a desirable form of cell therapy for the injured musculoskeletal tissue
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without requiring the use of immunosuppressive drugs during the treatments. Interestingly,
these cells, which are HLA class II negative, not only express both an immuno-privileged
and immuno-modulatory phenotype, but their HLA complex class I expression levels can al‐
so be manipulated, making them a potential cell source for MSC-based therapies. In addi‐
tion and as previously referred, these cells represent a non-controversial source of primitive
mesenchymal progenitor cells that can be harvested after birth, cryogenically stored,
thawed, and expanded for therapeutic uses. MSCs from the Wharton’s jelly display a high
proliferative rate and plasticity, being able to differentiate into adipocytes, osteoblasts, chon‐
drocytes, cardiomyocites, neurons, and glia. More recently, Conconi et al. [105] demonstrat‐
ed that CD105(+)/CD31(-)/KDR(-) cells are able not only to differentiate in vivo towards the
myogenic lineage as demonstrated by the co-localization of HLA 1 and sarcomeric tropo‐
myosine antigens, but also to contribute to the muscle regenerative process. These cells were
found to differentiate in vitro into myoblast-like cells, expressing Myf5 and MyoD after 7
and 11 days of myogenic induction, respectively. The timing of expression of Myf5 and My‐
oD in CD105(+)/CD31(-)/KDR(-) cells is similar to that described during embryonic develop‐
ment and in myoblast cultures [105].
Using the myectomy model we tested the use of Human MSCs isolated from the Wharton’s
jelly in order to improve skeletal muscle regeneration. The cells were directly infiltrated into
the lesion or delivered by different vehicles including Floseal®, Tisseel®, carboximetilcellu‐
lose (Sigma) and spherical hydrogel (own fabrication). MSC from Wharton’s jelly were pur‐
chased from PromoCell GmbH (C-12971, lot-number: 8082606.7). The MSCs are cultured
and maintained in a humidified atmosphere with 5% CO2 at 37ºC. Mesenchymal Stem Cell
Medium, PromoCell (C-28010) is replaced every 48 hours. At 90% confluence, cells are har‐
vested with 0.25% trypsin with EDTA (GIBCO) and passed into a new flask for further ex‐
pansion. MSCs at a concentration of 2 x 105cells are cultured exhibiting a 90% confluence
after 3-4 days. The application of human MSCs in rats is possible without inducing any im‐
munossupression in the experimental animals. The MSCs exhibited a normal star-like shape
with a flat morphology in culture (Figure 4). A total of 20 Giemsa-stained metaphases of
these cells, were analyzed for numerical aberrations. Sporadic, non-clonal aneuploidy was
found in 3 cells (41-45 chromosomes) the other 17 metaphases had 46 chromosomes. The
karyotype was determined in a completely analyzed G-banding metaphase and no structur‐
al alterations were found [57]. The karyotype analysis to the MSCs cell line derived from
Human Wharton jelly demonstrated that this cell line hasn’t neoplasic characteristics and is
stable during the cell culture procedures in terms of number and structure of the somatic
and sexual chromosomes. Also, the morphologic characteristics of these cells in culture, ob‐
served in an inverted microscope, are normal. These cells presented a star-like shape with a
flat morphology, characteristic of the MSCs been adequate to be used in in vivo rat experi‐
mental model [57]. The MSCs karyotype was studied in order to be sure that these cells did
not present any number or structure chromosome abnormalities due to isolation and cell
culture procedures before in vivo application. This concern was due to the negative effects
that some cellular systems, like the ESCs present, inducing the production of teratomas. The
cellular systems implanted into the injured skeletal muscle improved the skeletal muscle re‐
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generation since these cells produce growth factors, ECM molecules, and even modulate the
inflammatory process.
Figure 4. Undifferentiated MSCs from Wharton’s jelly, exhibiting a star-like shape with a flat morphology (100x mag‐
nification).
5. Evaluation of muscle regeneration
Muscle biopsies should be considered in order to obtain careful clinical assessment or for in‐
vestigation purposes. After the collection of the muscle samples, they should be immediate‐
ly equally divided in three. One sample should be placed into formalin (for hematoxilin and
eosin - HE), another sample should be fixed into 2.5% purified glutaraldehyde in 0.1M Sor‐
ensen phosphate buffer (for electron microscopy - EM) and the other sample should remain
unfixed and refrigerated (for histochemistry, biochemistry/genetics analysis).
5.1. Routine histological evaluation
Routine evaluation of the muscle biopsy sample involves the examination of formalin-fixed,
paraffin processed sections and unfixed frozen sections with standard histological and en‐
zyme histochemical stains at the light microscopic level. HE is the routine histological stain
used for evaluation of basic tissue organization and cellular structure. For HE, the whole
piece of tissue should be fixed in a clamp and after the tissue is infiltrated with wax, both
longitudinal and cross sections must be cut before embedding. Five levels should be ob‐
tained, especially in cases suspected of vasculitis. The parameters that can be evaluated are:
the type of inflammatory infiltrate present; examination of the structure of vessels walls
(vasculitis and/or fibrinoid necrosis); presence of endomysial and perimysial fibrosis/fatty
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infiltration; the range of fiber caliber; presence of angulated fibers; increase in number of
centrally located nuclei; central capillary migration; split fiber; group atrophy; necrotic/
myopathic (degenerating) fibers; atrophic fibers; regenerating fibers; target fibers; whorl fi‐
bers and ring fibers. The rounding of fiber contour and the variation of fiber diameter
should also be analyzed, however they are better evaluated with frozen sections (Figure 5).
Figure 5. HE staining of TA muscles 15 days post myectomy (A - control) and application of fibrin (B), hydrogel (C),
Floseal® (D).
5.1.1. Morphological analysis
Long-standing histological characteristics are still used to identify the mammalian skeletal
muscle regeneration process. On muscle cross-sections, these fundamental morphological
characteristics are newly formed myofibers of small caliber and with centrally located myo‐
nuclei. Newly formed myofibers are often basophilic (reflecting high protein synthesis) and
express embryonic/developmental forms of MHC (reflecting de novo fiber formation). On
muscle longitudinal sections and in isolated single muscle fibers, central myonuclei are ob‐
served in discrete portions of regenerating fibers or along the entire new fiber, suggesting
that cell fusion is not diffuse during regeneration but rather focal to the site of injury [1].
Cross-sectional area (CSA) analysis is one of the features that can be assessed. This can be
achieved with imaging software processing (Scio Image, ImageJ) of HE-stained muscle sec‐
tions. A predefined number of fibers is traced per sample and should be determined as ap‐
propriate by the examination of no additional changes in standard deviation. The
classification of small and large fibers can be determined for example by setting three stand‐
ard deviations from the mean CSA for the uninjured group at different time points [14]. The
CSA and number of myotubes can be used to estimate the development degree of muscle
regeneration following injury [36].




Collagen content in the wound bed can be calculated by image analysis of Masson’s Tri‐
chrome-stained histological images taken at a predefined image magnification. Color sepa‐
rations must be performed and an analysis threshold must be established for each image
series collected using the same brightness and white balance settings. Output images show‐
ing only computed blue coverage must be compared to the color images to ensure the repre‐
sentation of truly blue color due to collagen staining. As a control the analysis must be
performed on uninjured (control) skeletal muscle tissue sections stained with Masson’s Tri‐
chrome and collected using the same camera and threshold settings to confirm a collagen
content of zero for control tissue. The ratio of blue pixels above the threshold to total pixels
in the image is used to calculate the collagen content for each image [40].
5.1.3. International Standard (ISO 10993-6)
The International Standard (ISO 10993-6) specifies test methods for the assessment of the lo‐
cal effects after implantation of biomaterials intended for use in medical devices. These im‐
plantation tests are not intended to evaluate or determine the performance of the test
specimen in terms of mechanical or functional loading. The local effects are evaluated by a
comparison of the tissue response caused by the tested implant to that caused by the control.
The objective of the test methods is to characterize the history and evolution of the tissue
response after implantation of a medical device/biomaterial including final integration or re‐
sorption/degradation of the material. The test sample shall be implanted into the tissues
most relevant to the intended clinical use of the material. For short-term testing, animals
such as rodents or rabbits are commonly used. During the first two weeks after implantation
the reaction due to the surgical procedure itself may be difficult to distinguish from the tis‐
sue reaction evoked by the implant and for that reason in our study we collected the muscle
samples 15 days after implantation. For degradable/resorbable materials the test period shall
be related to the estimated degradation time of the test product. In our case the majority of
the vehicles/matrices tested the degradation time is less than 4 days. In the absence of com‐
plete degradation, absorption, or restoration to normal tissue structure and function, the
overall data collected may be sufficient to allow characterization of the local effects after im‐
plantation. A sufficient number of implants shall be inserted to ensure that the final number
of specimens to be evaluated will give valid results. The evaluation of the biological re‐
sponse must be accomplished by documenting the macroscopic and histopathological re‐
sponses as a function of time. The responses to the test sample must be compared to the
responses obtained at the control sample or sham operated sites. The scoring system used
for the histological evaluation shall take into account the extent of the area affected, either
quantitatively (e.g. in micrometres) or semi-quantitatively (Annex E of this Standard) [44,
106]. The biological response parameters, which shall be assessed and recorded, include:
i. the extent of fibrosis/fibrous capsule (layer in µm) and inflammation;
ii. the degeneration as determined by changes in tissue morphology;
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iii. the number and distribution as a function of distance from the material/tissue in‐
terface of the inflammatory cell types, namely polymorph nuclear neutrophilic leu‐
cocytes, lymphocytes, plasma cells, eosinophils, macrophages and multinucleated
cells;
iv. the presence, extent and type of necrosis;
v. other tissue alterations such as vascularization, fatty infiltration, granuloma forma‐
tion and bone formation;
vi. the material parameters such as fragmentation and/or debris presence, form and lo‐
cation of remnants of degraded material;
vii. the quality and quantity of tissue ingrowth, for porous and degradable implant
materials [106].
Under the conditions of the study and following the results for the mentioned parameters in
the semi-quantitative scoring system (Annex E of this Sandard), the test sample is consid‐
ered as non-irritant (0,0 up to 2,9), slight irritant (3,0 up to 8,9), moderate irritant (9,0 up to
15,0), severe irritant (> 15) to the tissue as compared to the negative control sample [106].
This test method is used for assessing the biological response of muscle tissue to an implant‐
ed material (Annex C of this Standard). As already mentioned, the method compares the bi‐
ological response to implants of test specimens with the biological response to implants of
control specimens. The control materials are those used in medical devices of which the clin‐
ical acceptability and biocompatibility characteristics have been established [106]. In our
study we developed an adaptation of this Standard by considering the control as the group
where the surgical procedure (myectomy) was performed without any biomaterial or cell
implantation (Figure 6). Although the surgical technique may profoundly influence the re‐
sult of any implantation procedure, we assumed that our standardized myectomy lesion
could be considered as the Control group since we were able to determine the local effects of
the different implants by their comparison to the minor effects of the surgical procedure.
The surgeries were executed under general anesthesia with a xylazine (1.25 mg/100 g BW
im) and ketamine (9 mg/100 g BW im) combination [38].
Figure 6. ISO 10993-6 scoring for the groups tested. The Control group obtained a score of 14.7 (in blue). Scorings above
the Control group were considered as non-irritant (in yellow), slight irritant (in orange) and moderate irritant (in red).




For histochemistry a basic panel should be performed, preferentially in frozen sections. De‐
pending on the objectives, an extended panel can be done concerning the study of some
molecules like the already mentioned Masson’s Trichrome-stain or enzyme processes such
as ATPase; NADH-TR or Esterase (Bancroft&Stevens). When necessary, other special stains
can be performed on paraffin sections.
5.3. Immunohistochemistry
In general, the immunohistochemical stains are utilized for the diagnosis of various muscu‐
lar dystrophies. They also may help to determine the subtypes of inflammatory cells within
an infiltrate or for other investigation purposes. Specific skeletal muscle markers such as
myosin heavy chain and desmin can be applied in order to clearly identify this tissue. The
distinction of SCs, considered as the reservoir of myogenic precursor cells, from other cells
must be made (like plasma cells, which may be occasionally seen under the basal lamina in
pathologic conditions). SCs can be easily demonstrated by immunostaining for N-CAM;
they also express vimentin. Activated SCs generally express Myo-D and myogenin [107].
The regenerating fibers express N-CAM, MyoD and myogenin, and also embryonic and ne‐
onatal isoforms of myosin heavy chain. In contrast to mature fibers, MCH class I histocom‐
patibility complex is expressed in regenerating fibers.
5.4. Immunofluorescence
For the preparation of TA muscles for immunofluorescence they should be embedded in
Tissue-Tek OCT compound. Sections are cut at 10 µm using a Leica CM1850 cryostat and
placed onto Surgipath microscope slides. Laminin-α2 chain is detected with a 1:500 dilu‐
tion of rabbit anti-laminin-α2 (2G) polyclonal antibody. The laminin-α1 chain is detected
with a rat anti-laminin-α1 monoclonal antibody. Primary rabbit antibodies are detected with
a 1:500 dilution of fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody and
the rat monoclonal antibody is detected with 1:500 dilution of fluorescein isothiocyanate-
conjugated  anti-rat  secondary  antibody.  In  all  immunofluorescence  experiments,  secon‐
dary  only  antibody  controls  are  included  to  test  for  specificity.  For  mouse  monoclonal
antibodies, endogenous mouse immunoglobulin is blocked with a mouse-on-mouse (MOM)
kit.  A 1-µg/ml concentration of tetramethylrhodamine-conjugated wheat germ agglutinin
(WGA) is used to define muscle fibers. To examine immune response, cytotoxic T cells are
detected with fluorescein isothiocyanate-labeled rat anti-mouse CD8a and macrophages are
detected with fluorescein isothiocyanateconjugated anti-mouse F4/80 at 1:1000 (Figure 7 and
Figure 8) [50].
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Figure 7. Double imunofluorescence staining for laminin and CD31.
Figure 8. Pax7+ SC counterstained with DAPI.
5.5. Electron microscopy
Electron microscopic (EM) examination of the glutaraldehyde-fixed portion of the biopsy is
performed when the light microscopic studies are inconclusive. Thus, it is reserved for se‐
lected circumstances in which the pathologist determines that EM has the potential of con‐
tributing significantly to determining a specific diagnosis. A specimen placed in
glutaraldehyde must be small, approximately 1-2 mm in width and depth, allowing the
complete tissue penetration by this fixative. Glutaraldehyde makes tissue brittle and inter‐
feres with immunohistochemical studies, so it is not appropriate for the paraffin specimen.
With EM, other muscle cell parameters can be analyzed in detail: the myofibril architecture;
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the plasma and sarcolemmal membrane; the mitochondria (size, density and shape); T-tu‐
bule; amount of lipid; nucleus; phagocytic granules and amount of glycogen. EM is extreme‐
ly useful in some cases: to identify inclusions primarily found by light microscopy; to help
in the characterization of stored material found on light microscopy and define its intracel‐
lular localization; to analyze structural abnormalities found by light microscopy; can assist
in the diagnosis of mitochondrial myopathy or seeking evidence to support a diagnosis of
dermatomyositis (EM can be used to look for tubuloreticular inclusion in endothelial cells
when light microscopic fails to reveal it).
5.6. Contraction force measurement
To obtain an estimate of total TA muscle strength reduced by the injury and possibly recov‐
ered by the cell/vehicle implants, contractile force due to electrical stimulation can be meas‐
ured before injury, after injury and at the time of sacrifice (at different time points) for non-
implanted and implanted animals. This can be accomplished with the animals under
general anesthesia and by anchoring the knee joint using a custom clamping system anch‐
ored to the floor of the surgical stereomicroscope stand and attaching a silk ligature to the
cleft between digits 1 and 2 that must be anchored to a transducer at the other end. This can
also be executed by cutting the TA tendon just before the insertion at the ankle and tying it
with a 4.0 nylon suture attached to the isometric transducer. The exposed muscle is stimulat‐
ed using 2 custom needle electrodes placed at the proximal muscle surface. Electrical stimu‐
lation of the TA muscle is applied at 5 volts, 4 ms pulse duration, at 500 ms intervals and the
resultant tetanic force recorded (200 points(s) using a BioPac MP-100 (Harvard Apparatus)
and accompanying software (AcknowledgeTM). The muscle must be kept hydrated during
the procedure using sterile saline. Maximum tetanic force is measured by reducing the stim‐
ulation interval to 20 ms, generating continuous stimulation simulating tetanus condition.
Another method of applying the electrical stimulation can be obtained by exposing the sciat‐
ic nerve with an incision in the hamstring region The tibial nerve is cut just after the sciatic
nerve splits into the tibial and peroneal nerves to eliminate any contraction from the gastro‐
cnemius muscle causing background in the force data. The exposed sciatic nerve is then laid
over two electrodes with a small piece of parafilm and should also be kept moist with peri‐
odic treatment of mineral oil. Stimulation is made using a supra-maximal square-wave
pulse of 0.1 ms duration. Measurements are performed at the length at which maximal ex‐
tension is obtained during the twitch and the data should be recorded for sub-maximal and
maximal isometric force. Specific maximal force should be quantified by correcting for mus‐
cle mass [40, 98].
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